Inhibrx. has filed a patent for VHH-containing polypeptides that bind CD33. The patent also covers various uses of these polypeptides. GlobalData’s report on Inhibrx gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
Discover B2B Marketing That Performs
Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.
According to GlobalData’s company profile on Inhibrx, Personalized cancer vaccines was a key innovation area identified from patents. Inhibrx's grant share as of September 2023 was 27%. Grant share is based on the ratio of number of grants to total number of patents.
Vhh-containing polypeptides that bind cd33
A recently filed patent (Publication Number: US20230312716A1) describes an isolated nucleic acid that encodes a polypeptide with at least one VHH domain that binds CD33. The patent claims specify various combinations of amino acid sequences for the CDR1, CDR2, and CDR3 regions of the VHH domain. These combinations are identified by specific SEQ ID numbers. The patent also mentions that the VHH domain can be humanized and can have an amino acid sequence that is at least 90% identical to certain specified sequences.
The patent further states that the polypeptide can have one, two, or three VHH domains and can also include a binding domain for an antigen other than CD33. The binding domains mentioned include CD3, T-cell receptor (TCR) a, TCRß, CD28, CD16, CD32A, CD64, CD89, NKp46, or NKG2D. Additionally, the polypeptide can have an Fc region with a specific amino acid sequence.
The patent also covers a vector that contains the isolated nucleic acid and a host cell that contains the isolated nucleic acid. The host cell can be incubated under suitable conditions to express the polypeptide, which can then be isolated.
In summary, the patent describes an isolated nucleic acid that encodes a polypeptide with at least one VHH domain that binds CD33. The patent claims specify various combinations of amino acid sequences for the CDR1, CDR2, and CDR3 regions of the VHH domain. The polypeptide can have one, two, or three VHH domains and can also include a binding domain for an antigen other than CD33. The patent also covers a vector and a host cell containing the isolated nucleic acid, as well as a method of producing the polypeptide.
To know more about GlobalData’s detailed insights on Inhibrx, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
